Ginkgo Bioworks was founded in 2008 by Jason Kelly, Reshma Shetty, Barry Canton, Austin Che, and Tom Knight. The company has not officially endorsed a plan to participate in an IPO.
Ginkgo specializes in leveraging biological processes in organisms to meet the needs of their clients in industries ranging from cosmetics to food goods. Their website claims the firm’s expertise is in cultured ingredients, strain improvement, and enzymes. The company has raised nearly $800 million in Venture Capital funding from investors including Reshape Holdings, T. Rowe Price, Innovation Camp, Illumia, Power Gate Ventures, Alrai Capital, OS Fund, Azure Capital Partners, Data Collective, Felicis Ventures, Vast Ventures, and Y Combinator. Per company press releases, Ginko last raised a Series E expansion in May 2020 bringing the round total to $360 million at a post-money valuation of nearly $5 billion.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
05/28/2020 | Series E | $360MM | $xx.xx | $4.89B | Allen & Company, Baillie Gifford, Cascade Investment, General Atlantic, Illumina, Reshape Holdings, T. Rowe Price, Viking Global Investors | |
Price per Share
$xx.xx
Shares Outstanding
2,396,964
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Allen & Company, Baillie Gifford, Cascade Investment, General Atlantic, Illumina, Reshape Holdings, T. Rowe Price, Viking Global Investors
|
||||||
12/14/2017 | Series D | $275MM | $xx.xx | $1.57B | Cascade Investment, General Atlantic, Viking Global Investors, Vital Venture Capital, Y Combinator | |
Price per Share
$xx.xx
Shares Outstanding
5,763,991
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Cascade Investment, General Atlantic, Viking Global Investors, Vital Venture Capital, Y Combinator
|
||||||
06/08/2016 | Series C | $98.9MM | $xx.xx | $450MM | Allen & Company, Alrai Capital, Baillie Gifford, Cascade Investment, Casdin Capital, Senator Investment Group, Viking Global Investors, Y Combinator | |
Price per Share
$xx.xx
Shares Outstanding
4,658,503
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Allen & Company, Alrai Capital, Baillie Gifford, Cascade Investment, Casdin Capital, Senator Investment Group, Viking Global Investors, Y Combinator
|
||||||
07/08/2015 | Series B | $51.63MM | $xx.xx | $200MM | Chinarock Capital Management, Data Collective, Felicis Ventures, Id Ventures America, Iglobe Partners, Ken Arnold, Massventures, Os Fund, Vast Ventures, Viking Global Investors, Y Combinator | |
Price per Share
$xx.xx
Shares Outstanding
4,024,260
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Chinarock Capital Management, Data Collective, Felicis Ventures, Id Ventures America, Iglobe Partners, Ken Arnold, Massventures, Os Fund, Vast Ventures, Viking Global Investors, Y Combinator
|